Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.

Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.

Mentioned on this episode: 

• Mantle Cell Lymphoma
• Mantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should Know episode
• CAR T cell Therapy
• Highlights from ASH conference

Additional LLS Support Resources: 

• Information Specialists
• Financial support
• Free telephone/web patient programs 
• Patti Robinson Kaufmann First Connection Program
• Free booklets 
• LLS Public Policy & Advocacy
• Clinical Trial Support Center
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Free Nutrition Consultations 
• LLS Advocacy
• Survivorship Workbook

Support for this episode provided by Bristol Myers Squibb; CRISPR Therapeutics; Janssen Oncology & Legend Biotech; KITE, a Gilead Company and Novartis Pharmaceuticals Corporation.

The post Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy appeared first on The Bloodline with LLS.